FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer FDA approves darolutamide (Nubeqa) for mCSPC: 46% reduction in disease progression risk vs placebo in ARANOTE trial.View More
How Low Do You Need to Go? Association Between Various PSA Response Measures and Clinical Outcomes in mCSPC in the Veteran Health Administration (VHA) Data PSA nadir
